These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11365728)

  • 1. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifapentine for the treatment of pulmonary tuberculosis.
    Munsiff SS; Kambili C; Ahuja SD
    Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Older antibiotic gains new respect as potent treatment for tuberculosis. Rifapentine is already approved for use with humans.
    Nuermberger E
    Home Healthc Nurse; 2008 Apr; 26(4):204-5. PubMed ID: 18408506
    [No Abstract]   [Full Text] [Related]  

  • 5. Rifapentine--a long-acting rifamycin for tuberculosis.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
    [No Abstract]   [Full Text] [Related]  

  • 6. Fomivirsen approved for CMV retinitis.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):14-6. PubMed ID: 11365956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong.
    Tam CM; Chan SL; Lam CW; Dickinson JM; Mitchison DA
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):411-6. PubMed ID: 9441094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Researchers find new drugs to fight MAC.
    AIDS Alert; 1995 Nov; 10(11):138-9. PubMed ID: 11362925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tuberculosis drug development. How can we do better?
    O'Brien RJ; Vernon AA
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1705-7. PubMed ID: 9620895
    [No Abstract]   [Full Text] [Related]  

  • 10. [Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis].
    Chu N; Yan B; Zhu L
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jul; 21(7):388-91. PubMed ID: 11326873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of multidrug-resistant tuberculosis treatment in HIV-positive patients in New York City, 1990-1997.
    Frieden TR; Munsiff SS; Ahuja SD
    Int J Tuberc Lung Dis; 2007 Jan; 11(1):116. PubMed ID: 17217141
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of rifapentine: the way ahead.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):612-5. PubMed ID: 9712273
    [No Abstract]   [Full Text] [Related]  

  • 13. [A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous].
    He GJ
    Zhonghua Jie He He Hu Xi Za Zhi; 1993 Feb; 16(2):73-6, 122. PubMed ID: 8251027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management strategies for candidates for protease inhibitors and requiring treatment for Mycobacterium tuberculosis. TB/HIV Advisory Committee.
    Can Commun Dis Rep; 1998 May; 24(10):77-80. PubMed ID: 9613030
    [No Abstract]   [Full Text] [Related]  

  • 15. New drugs for tuberculosis treatment.
    Sánchez F; López Colomés JL; Villarino E; Grosset J
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():47-56. PubMed ID: 21420567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India.
    Swaminathan S; Padmapriyadarsini C; Sukumar B; Iliayas S; Kumar SR; Triveni C; Gomathy P; Thomas B; Mathew M; Narayanan PR
    Clin Infect Dis; 2008 Mar; 46(6):946-9. PubMed ID: 18279043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis: guidelines changed for latent TB treatment.
    AIDS Treat News; 2001 Sep; (371):3. PubMed ID: 11668976
    [No Abstract]   [Full Text] [Related]  

  • 19. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
    Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
    Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KS drug goes to FDA. Food and Drug Administration.
    GMHC Treat Issues; 1998 May; 12(5):7. PubMed ID: 11365479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.